SUN11602 manufacturers
- SUN11602
-
- $48.00 / 5mg
-
2026-01-16
- CAS:704869-38-5
- Min. Order:
- Purity: 98.43%
- Supply Ability: 10g
|
| | SUN11602 Basic information |
| Product Name: | SUN11602 | | Synonyms: | SUN11602;4-[[4-[[2-[(4-Amino-2,3,5,6-tetramethylphenyl)amino]acetyl]methylamino]-1-piperidinyl]methyl]benzamide;CS-2504;SUN11602;SUN11602;inhibit,Fibroblast growth factor receptor,SUN11602,FGFR,Inhibitor,SUN-11602;Benzamide, 4-[[4-[[2-[(4-amino-2,3,5,6-tetramethylphenyl)amino]acetyl]methylamino]-1-piperidinyl]methyl]-;SUN11602, 10 mM in DMSO;4-[[4-[[2-(4-amino-2,3,5,6-tetramethylanilino)acetyl]-methylamino]piperidin-1-yl]methyl]benzamide | | CAS: | 704869-38-5 | | MF: | C26H37N5O2 | | MW: | 451.60428 | | EINECS: | | | Product Categories: | | | Mol File: | 704869-38-5.mol |  |
| | SUN11602 Chemical Properties |
| Boiling point | 679.8±55.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A crystalline solid | | pka | 16.19±0.50(Predicted) | | color | Light yellow to yellow | | InChI | 1S/C26H37N5O2/c1-16-18(3)25(19(4)17(2)24(16)27)29-14-23(32)30(5)22-10-12-31(13-11-22)15-20-6-8-21(9-7-20)26(28)33/h6-9,22,29H,10-15,27H2,1-5H3,(H2,28,33) | | InChIKey | KCODNOOPOPTZMO-UHFFFAOYSA-N | | SMILES | N2(CCC(CC2)N(C)C(=O)CNc3c(c(c(c(c3C)C)N)C)C)Cc1ccc(cc1)C(=O)N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | SUN11602 Usage And Synthesis |
| Uses | SUN 11602 is a novel aniline compound, which mimics the neuroprotective mechanisms of basic fibroblast growth factor. | | Biological Activity | SUN11602 is an orally active basic fibroblast growth factor (bFGF, FGF2) mimetic th at protects against glutamate toxicity in primary r at cerebrocortical neuron (0.1-1 μM SUN11602; 150 μM glutamate) and murine hippocampal neuron cultures (0.3-3 μM SUN11602; 100 μM glutamate). When administered in vivo, SUN11602 exhibits therapeutic efficacy in a r at hippocampal-lesion model (1-10 mg/kg p.o. 24h post Aβ1-40 injection) and a murine MPTP-induced nigrostriatal degeneration model (2.5-5 mg/kg/day p.o.). | | in vivo | In WT mice, SUN11602 increases the levels of newly synthesized Calb in cerebrocortical neurons and suppresses the glutamate-induced rise in intracellular Ca2+. This Ca2+-capturing ability of Calb allows the neurons to survive severe toxic conditions of glutamate[1]. Oral administration of SUN11602 at the midpoint of Aβ1-40 and ibotenate injections attenuate short-term memory impairment in the Y-maze test, as well as spatial learning deficits in the water maze task. In addition, the SUN11602 treatment inhibits the increase of peripheral-type benzodiazepine-binding sites (PTBBS),which are a marker for gliosis[3]. |
| | SUN11602 Preparation Products And Raw materials |
|